Table 3.

Ongoing randomized Phase III studies of supportive care in adult acute lymphoblastic leukemia (ALL).

Study groupStudy nameAge range, yMain study questions/aims
MDACC ID01-592 No age restrictions Erythropoetin versus supportive care (all types receiving hyper-CVAD or augmented BFM regimens). 
MDACC ID03-0124 ≥ 18 Atonal vs. placebo for prevention of bone loss during hyper-CVAD 
MDACC 2004-0107 ≥ 15 Tight control of glucose during hyper-CVAD. 
GMALL GMALL08 ≥ 15 Rasburicase vs. allopurinol during induction. 
Study groupStudy nameAge range, yMain study questions/aims
MDACC ID01-592 No age restrictions Erythropoetin versus supportive care (all types receiving hyper-CVAD or augmented BFM regimens). 
MDACC ID03-0124 ≥ 18 Atonal vs. placebo for prevention of bone loss during hyper-CVAD 
MDACC 2004-0107 ≥ 15 Tight control of glucose during hyper-CVAD. 
GMALL GMALL08 ≥ 15 Rasburicase vs. allopurinol during induction. 
Close Modal

or Create an Account

Close Modal
Close Modal